Evaluation of Outcomes and Toxicities of Commercial Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Real-World Evidence (RWE) from 10 US Academic Centers
Year: 2024
Type: conference-abstract
Source: Blood
Authors: John Sharp, Paolo Strati, Subodh Bhatta, Jennifer J. Huang, Colin Thomas, Daniel K Reef, Alexander Gorzewski, Catherine Reinert, Andinet Teferra, Ari Pelcovits, Thomas Ollila, Joseph E. Maakaron, Manali K. Kamdar, Lindsey Fitzgerald, Reem Karmali, Natalie Grover, Stefan K. Barta, Timothy Voorhees, Mazyar Shadman, Sairah Ahmed, Narendranath Epperla
Institutions: The Ohio State University, The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Thomas Jefferson University Hospital, University of North Carolina at Chapel Hill, University of Colorado Cancer Center, University of Minnesota, Rhode Island Hospital, Brown University, University of Minnesota Medical Center, University of Colorado Denver, University of Utah, Huntsman Cancer Institute, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fox Chase Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405040573